 |
市场调查报告书
商品编码
1550765
全球醋酸环丙孕酮市场：按剂型、应用、地区Cyproterone Acetate Market, By Formulation, By Application, By Geography |
||||||
价格
简介目录
预计2024年全球醋酸环丙孕酮市场规模为3.271亿美元，预计2031年将达4.451亿美元，2024年至2031年复合年增长率为4.5%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 3.271 亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测 2024-2031 年复合年增长率： | 4.50% | 2031年价值预测 | 4.451 亿美元 |
图：2024 年按地区分類的醋酸环丙孕酮市场占有率(%)
醋酸环丙孕酮 (CPA) 是一种黄体素和抗雄性激素类固醇药物，主要用于治疗前列腺癌、早熟症、痤疮和女性毛髮过度生长。它作为黄体酮促效剂或拮抗剂，并通过与雄激素受体竞争作为抗雄激素。 CPA是临床上最早使用的抗雄性激素药物之一，至今仍是临床使用的重要药物。它在世界各地以多种品牌出售，包括单独销售和与雌激素联合销售。
市场动态：
全球醋酸环丙孕酮市场受到男性前列腺癌发病率上升以及女性痤疮和多毛症病例增加的推动。此外，生活方式的改变和老年人口的增加是推动市场成长的主要因素。然而，长期使用醋酸环丙孕酮的副作用，如肝毒性、疲劳和忧郁症，以及替代药物的出现，预计将在一定程度上阻碍市场扩张。开发具有改进安全性的共轭 CPA 可能会在预测期内创造利润丰厚的机会。
本研究的主要特点
- 本报告对全球醋酸环丙孕酮市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
- 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
- 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球醋酸环丙孕酮市场的主要企业概况。
- 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 醋酸环丙孕酮全球市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 透过用于分析全球醋酸环丙孕酮市场的各种策略矩阵，将促进相关人员的决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特的分析
- 併购场景
第四章全球醋酸环丙孕酮市场：依配方分类（2024-2031）
- 锭剂
- 注射
- 局部製剂
第五章全球醋酸环丙孕酮市场：依应用分类（2024-2031）
- 荷尔蒙补充疗法
- 避孕
- 痤疮治疗
- 其他的
第六章全球醋酸环丙孕酮市场：按地区（2019-2031）
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 南非
- 北非
- 中部非洲
第七章 竞争格局
- Curia
- Axplora
- LGM Pharma
- Hubei Gedian Humanwell Pharmaceutical
- Cipla
- NEWCHEM SPA
- Swati Spentose
- Teva API
- Teva Pharmaceutical Industries
- Unipex
- Zhejiang Xianju Pharmaceutical Co. Ltd
- KRKA
- Cambrex
- Sicor De Mexico
- Zhejiang Xianju Xianle
- Shaoxing Hantai Pharma
- Farmabios
第八章 分析师建议
- Wheel of Fortune
- 分析师观点
- Coherent Opportunity Map（COM）
第9章 参考文献及调查方法
- 参考
- 调查方法
- 关于出版商
简介目录
Product Code: CMI7287
The global cyproterone acetate market is estimated to be valued at USD 327.1 Mn in 2024 and is expected to reach USD 445.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 327.1 Mn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.50% | 2031 Value Projection: | US$ 445.1 Mn |
Figure. Cyproterone Acetate Market Share (%), By Region 2024
Cyproterone acetate (CPA) is a progestogen and antiandrogen steroid medication that is used primarily in the treatment of prostate cancer, precocious puberty, acne, and excessive hair growth in women. It acts as a progesterone agonist or antagonist and as an antiandrogen by competing for the androgen receptor. CPA was one of the earliest clinically used antiandrogens and remains an important medication in clinical use today. It is available both as a standalone medication and in combination with an estrogen under various brand names throughout the world.
Market Dynamics:
The global cyproterone acetate market is driven by the increasing incidence of prostate cancer in men, and rising cases of acne and hirsutism in women. Moreover, shifting lifestyle patterns and growing geriatric population are major factors fueling the market growth. However, side effects associated with the long-term use of cyproterone acetate such as liver toxicity, fatigue, and depression along with the availability of alternative medications are expected to hamper market expansion to some extent. The development of conjugated forms of CPA with improved safety profiles can create lucrative opportunities over the forecast period.
Key Features of the Study:
- This report provides in-depth analysis of the global cyproterone acetate market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cyproterone acetate market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Curia, Axplora, LGM Pharma, Hubei Gedian Humanwell Pharmaceutical, Cipla, NEWCHEM SPA, Swati Spentose, Teva API, Teva Pharmaceutical Industries, Unipex, Zhejiang Xianju Pharmaceutical Co. Ltd, KRKA, Cambrex, Sicor De Mexico, Zhejiang Xianju Xianle, Shaoxing Hantai Pharma, and Farmabios
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cyproterone acetate market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cyproterone acetate market
Detailed Segmentation:
- Formulation Insights (Revenue, USD Mn, 2019 - 2031)
- Tablets
- Injectables
- Topical Preparations
- Application Insights (Revenue, USD Mn, 2019 - 2031)
- Hormonal Replacement Therapy
- Contraception
- Acne Treatment
- Others
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Curia
- Axplora
- LGM Pharma
- Hubei Gedian Humanwell Pharmaceutical
- Cipla
- NEWCHEM SPA
- Swati Spentose
- Teva API
- Teva Pharmaceutical Industries
- Unipex
- Zhejiang Xianju Pharmaceutical Co. Ltd
- KRKA
- Cambrex
- Sicor De Mexico
- Zhejiang Xianju Xianle
- Shaoxing Hantai Pharma
- Farmabios
Table of Contents
1. RESEARCH OBJECTIVES AND ASSUMPTIONS
- Research Objectives
- Assumptions
- Abbreviations
2. MARKET PURVIEW
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cyproterone Acetate Market, By Formulation
- Global Cyproterone Acetate Market, By Application
3. MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Cyproterone Acetate Market, By Formulation, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Injectables
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Topical Preparations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Global Cyproterone Acetate Market, By Application, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hormonal Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Contraception
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Acne Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Cyproterone Acetate Market, By Region, 2019 - 2031, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Formulation , 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Application , 2019 - 2031, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
7. COMPETITIVE LANDSCAPE
- Curia
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Axplora
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LGM Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hubei Gedian Humanwell Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NEWCHEM SPA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Swati Spentose
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva API
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Unipex
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zhejiang Xianju Pharmaceutical Co. Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- KRKA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cambrex
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sicor De Mexico
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zhejiang Xianju Xianle
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shaoxing Hantai Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Farmabios
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
8. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. References and Research Methodology
- References
- Research Methodology
- About us
